Population Pharmacokinetic Analysis of Selumetinib and Its N-desmethyl Metabolite in Japanese and Non-Japanese Pediatric Patients with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Figure 4

Model-predicted steady-state exposure. The dots represent the model-predicted exposure for each patient. The boxplots summarize those exposures. Japanese: patients enrolled in the Japanese phase I trial (D1346C00013); non-Japanese: patients enrolled in SPRINT phase II stratum 1. The p values were determined using the exact Wilcoxon rank-sum test. AUCss: area under the concentration-time curve over a dosage interval at steady state; and Cmax,ss: peak plasma concentration at steady state.